Related Experiment Videos
Summary
Ketoconazole effectively treats metastatic prostate cancer by rapidly lowering testosterone and adrenal androgens. This antifungal agent offers a well-tolerated, new treatment option for advanced prostate cancer patients.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Metastatic prostate cancer (stage D2) requires effective treatments.
- Hormonal therapies are crucial for managing prostate cancer progression.
- Nonestrogenic agents offer alternative therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of ketoconazole in patients with metastatic prostate cancer.
- To assess the impact of ketoconazole on androgen levels and clinical markers.
- To determine the safety and tolerability of ketoconazole in this patient group.
Main Methods:
- 13 patients with symptomatic stage D2 prostate cancer received ketoconazole (400 mg orally every 8 hours).
- Serum testosterone, androstenedione, and dehydroepiandrosterone levels were monitored.
- Clinical response, pain levels, and serum prostatic acid phosphatase were assessed.
Main Results:
- Ketoconazole rapidly decreased serum testosterone to castrate levels within 24 hours.
- Significant reductions in adrenal androgens (androstenedione, dehydroepiandrosterone) were observed.
- All patients showed clinical improvement, pain reduction, and decreased prostatic acid phosphatase within 1 week, normalizing by 1 month.
- No relapses occurred during 3-10 months of follow-up.
- Side effects were minimal.
Conclusions:
- Ketoconazole demonstrates rapid and significant efficacy in treating metastatic prostate cancer.
- The drug effectively reduces both testicular and adrenal androgen production.
- Ketoconazole presents a well-tolerated and potentially important new therapeutic option for advanced prostate cancer due to its ease of administration and rapid action.